Granite Ridge Resources Schedules Second Quarter 2025 Earnings Conference Call
Instructions on how to access the webcast and conference call are shown below.
About Granite Ridge
Granite Ridge is a scaled energy company which aims to provide shareholders with exposure similar to energy private equity through operated partnerships and traditional non-operated assets. We own assets in six prolific unconventional basins across the United States. We aim to deliver a diversified portfolio with best-in-class full cycle returns by investing in a large number of high-graded deals developed by proven public and private operators. We focus on success as measured by total shareholder returns, which we seek to balance with a low leverage profile. For more information, visit Granite Ridge's website at www.graniteridge.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
5 minutes ago
- Toronto Sun
Saskatchewan Premier Moe, federal minister to meet on China canola tariff
Published Aug 21, 2025 • 1 minute read Saskatchewan Premier Scott Moe holds a press conference after the first ministers' meeting at TCU Place in Saskatoon, Sask. on Monday, June 2, 2025. Photo by Michelle Berg / Postmedia Network SASKATOON — Saskatchewan Premier Scott Moe is set to meet today with federal Agriculture Minister Heath MacDonald, along with industry groups, to discuss the steep Chinese tariff on Canadian canola seed. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Kody Blois, the parliamentary secretary for Prime Minister Mark Carney, and Saskatchewan Agriculture Minister Daryl Harrison are also to attend the meeting in Saskatoon. A press conference is scheduled following the discussion. China imposed the tariff of nearly 76 per cent last week, causing the price of one of Canada's most valuable crops to fall and wiping out millions of dollars in its value. It comes one year after China launched an anti-dumping investigation into Canadian canola, a move in response to Canada's 100 per cent tariff on Chinese electric vehicles. Farmers and Ottawa have rejected the dumping claim, saying exporters have followed rules-based trade. Read More Sunshine Girls Sunshine Girls Columnists Toronto Maple Leafs Toronto & GTA
CTV News
5 minutes ago
- CTV News
Tiger Woods to lead group that could reshape the PGA Tour's competitive model
Tiger Woods waves after his final round at the Masters golf tournament at Augusta National Golf Club Sunday, April 14, 2024, in Augusta, Ga. (AP Photo/David J. Phillip) ATLANTA — Tiger Woods is a major player in golf again, this time without clubs. He was appointed Wednesday to chair a new committee charged with taking a fresh look at the competitive model for how the PGA Tour runs its tournaments. Brian Rolapp, three weeks into his role as the tour's first CEO, announced the nine-member 'Future Competition Committee' and said it would have a clean sheet to consider changes that uphold traditions without being tied to them. 'This is about shaping the next era of the PGA Tour,' Woods said in a social media post. Rolapp didn't have details on several issues he faces as he takes over for Commissioner Jay Monahan, including the future of a sport that has been splintered by Saudi money that created the rival LIV Golf League and lured away a number of top players. The PGA Tour's negotiations with the Public Investment Fund have stalled, and Rolapp did not make that sound as if it were a top priority when asked about the fans' desire to see all the best players together more often. 'I'm going to focus on what I can control,' Rolapp said. 'I would offer to you that the best collection of golfers in the world are on the PGA Tour. I think there's a bunch of metrics that demonstrate that, from rankings to viewership to whatever you want to pick. I'm going to lean into that and strengthen that. 'I will also say that to the extent we can do anything that's going to further strengthen the PGA Tour, we'll do that,' he said. 'And I'm interested in exploring whatever strengthens the PGA Tour.' Woods, who has played only 10 times on the PGA Tour since his February 2021 car crash and has been out all of this year with a ruptured Achilles tendon, already serves on the PGA Tour board without a term limit. Now he will lead five players from the board — Patrick Cantlay, Adam Scott, Camilo Villegas, Maverick McNealy and Keith Mitchell — along with three from the business side. That includes baseball executive Theo Epstein. Rolapp is not trying to reinvent a sport that held its first championship in 1860. He said among his early observations, after two decades at the NFL, was the strength and momentum of the PGA Tour. 'My key takeaway when you boil all this down is that the strength of the PGA Tour is strong, but there's much more we need to do, much more we need to change for the benefit of fans, players and our partners,' he said. He said the committee would be guided by parity (he conceded golf already has that), scarcity and simplicity. The tour released a 2026 schedule on Tuesday that adds another US$20-million signature event, this one to Trump National Doral, as part of a 35-event schedule from January through August. Rolapp said the simplicity was mostly about connecting the regular season to the postseason. He referred to the committee's work as a 'holistic relook of how we compete on the tour' during the regular season, postseason and offseason. 'The goal is not incremental change,' he said. 'The goal is significant change.' He did not set a timetable for any of it. The Tour Championship ends this week at East Lake for the top 30 players. The tour has eliminated the built-in advantage for top seeds so that everyone starts from scratch. The committee is a smaller version of the PGA Tour Enterprises board and policy board. Joining Epstein from the business side are board chairman Joe Gorder and John Henry of Fenway Sports Group, who leads the Strategic Sports Group that invested $1.5 billion — with the potential to double that — into the tour in a minority investment announced 18 months ago. Rolapp said he had a lot of ideas how to the use the money but none he was ready to share. But he said the involvement of SSG was a big reason he took the job. 'Not only does it provide necessary capital as we work through this competitive model and improved commercial model, I also think it also brings learnings from other sports, which I think is beneficial ... to grow the PGA Tour. 'I think outside perspective is always a very good thing, as long as it's applied in the right way. I think SSG has brought that and has been helpful.' ___ Doug Ferguson, The Associated Press
Globe and Mail
5 minutes ago
- Globe and Mail
Satellos to Participate in Four September Institutional and Retail Investor Conferences
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today that members of its senior management team will participate in the following investor events in September: Wells Fargo Healthcare Conference Format: Participation in 1x1 meetings Date: Wednesday, Sept. 3 Location: Boston, MA Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat and 1x1 meetings Date: Friday, Sept. 5, 10:55 ET Location: New York, NY H.C. Wainwright Global Investment Conference Format: Participation in 1x1 meetings Date: Tuesday, Sept. 9 Location: New York, NY Morgan Stanley Global Healthcare Conference Format: Fireside Chat and 1x1 meetings Date: Wednesday, Sept. 10, 9:15 ET Location: New York, NY Should any retail or institutional investors wish to connect directly with us in person, please reach out to us at ir@ The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentations. ABOUT SATELLOS BIOSCIENCE INC. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit NOTICE ON FORWARD-LOOKING STATEMENTS This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective', 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
